Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:23:36 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:MRTX from 2023-04-27 to 2024-04-26 - 36 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-01-10 08:00U:MRTXNews ReleaseEuropean Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
2023-11-10 07:30U:MRTXNews ReleaseMirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
2023-11-06 16:51U:MRTXSEDAR Interim MD & ASEDAR Interim MD & A
2023-11-06 16:42U:MRTXSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-11-06 08:00U:MRTXNews ReleaseMirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
2023-11-03 17:19U:MRTXNews ReleaseMirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
2023-11-02 07:30U:MRTXNews ReleaseKura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRAS ¡ ´ ³ ‚ ¹ ‚ ² ¡ ¶ œ-Mutated NSCLC
2023-10-17 16:00U:MRTXNews ReleaseMirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC)
2023-10-08 17:16U:MRTXNews ReleaseBristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
2023-09-27 16:30U:MRTXNews ReleaseMirati To Present Updated Clinical Data at ESMO Congress 2023
2023-09-09 22:35U:MRTXNews ReleaseMirati Presents Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response and Long-Term Overall Survival at 2023 World Conference on Lung Cancer
2023-09-05 16:01U:MRTXNews ReleaseMirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2023-08-29 16:00U:MRTXNews ReleaseMirati Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference
2023-08-23 16:00U:MRTXNews ReleaseMirati Therapeutics Announces Departure of Chief Financial Officer Laurie Stelzer
2023-08-21 16:00U:MRTXNews ReleaseMirati To Present Pooled Clinical Data from Adagrasib's KRYSTAL-1 Study Demonstrating Overall Survival Results at Two-Years of Follow-Up at 2023 World Conference on Lung Cancer
2023-08-11 16:00U:MRTXNews ReleaseMirati Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
2023-08-09 16:00U:MRTXNews ReleaseCancer Discovery Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers through Novel Approach to MTA-Cooperative PRMT5 Inhibition
2023-08-09 00:31U:MRTXNews ReleaseMirati Therapeutics Announces Pricing of Upsized Public Offering
2023-08-08 17:46U:MRTXSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-08-08 16:02U:MRTXNews ReleaseMirati Therapeutics Announces Proposed Public Offering
2023-08-08 16:01U:MRTXNews ReleaseMirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
2023-08-08 16:00U:MRTXNews ReleaseMirati Therapeutics Announces Departure of Chief Executive Officer David Meek
2023-08-03 16:01U:MRTXNews ReleaseMirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2023-07-25 16:30U:MRTXNews ReleaseMirati Therapeutics ‚ ® to Report Second Quarter 2023 Financial Results and Recent Corporate Updates on August 8, 2023
2023-07-21 07:56U:MRTXNews ReleaseMirati Therapeutics Provides Update on Regulatory Review in the European Union of KRAZATI (adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRAS G12C Mutation
2023-06-23 16:00U:MRTXNews ReleaseMirati Therapeutics Appoints Industry Veteran Carol Gallagher, Pharm.D. as New Independent Director
2023-06-20 08:00U:MRTXNews ReleaseJournal of Clinical Oncology Publishes Clinical Results of Adagrasib as a Targeted Treatment for KRASG12C-Mutated NSCLC with Untreated Central Nervous System (CNS) Metastases
2023-06-01 16:30U:MRTXNews ReleaseMirati Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023
2023-05-30 16:00U:MRTXNews ReleaseMirati To Encore Compelling Clinical Data Demonstrating Adagrasib's Potential as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors at 2023 ASCO Annual Meeting
2023-05-24 16:01U:MRTXNews ReleaseMirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO ‚ ®
2023-05-09 18:32U:MRTXSEDAR MD & ASEDAR MD & A
2023-05-09 18:26U:MRTXSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-05-09 16:01U:MRTXNews ReleaseMirati Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Updates
2023-05-08 08:30U:MRTXNews ReleaseMirati Therapeutics and Sarah Cannon Research Institute Announce Strategic, Community Site Focused Partnership to Increase Diversity in Oncology Clinical Studies
2023-05-05 16:00U:MRTXNews ReleaseMirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2023-04-27 16:30U:MRTXNews ReleaseMirati Therapeutics to Participate at the Bank of America Securities 2023 Health Care Conference